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INTRODUCTION
Reporter genes play essential roles in biological research, 
such as allowing visualization of gene expression and 
tracking the migration of living cells (1, 2). A variety of 
reporter genes are currently available, and fluorescent 
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Objective: Recent innovations in biology are boosting gene and cell therapy, but monitoring the response to these treatments 
is difficult. The purpose of this study was to find an MRI-reporter gene that can be used to monitor gene or cell therapy and 
that can be delivered without a viral vector, as viral vector delivery methods can result in long-term complications.
Materials and Methods: CMV promoter-human organic anion transporting polypeptide 1B3 (CMV-hOATP1B3) cDNA or CMV-blank 
DNA (control) was transfected into HEK293 cells using Lipofectamine. OATP1B3 expression was confirmed by western blotting 
and confocal microscopy. In vitro cell phantoms were made using transfected HEK293 cells cultured in various concentrations of 
gadoxetic acid for 24 hours, and images of the phantoms were made with a 9.4T micro-MRI. In vivo xenograft tumors were made 
by implanting HEK293 cells transfected with CMV-hOATP1B3 (n = 4) or CMV-blank (n = 4) in 8-week-old male nude mice, and 
MRI was performed before and after intravenous injection of gadoxetic acid (1.2 μL/g).
Results: Western blot and confocal microscopy after immunofluorescence staining revealed that only CMV-hOATP1B3-transfected 
HEK293 cells produced abundant OATP1B3, which localized at the cell membrane. OATP1B3 expression levels remained high 
through the 25th subculture cycle, but decreased substantially by the 50th subculture cycle. MRI of cell phantoms showed 
that only the CMV-hOATP1B3-transfected cells produced a significant contrast enhancement effect. In vivo MRI of xenograft 
tumors revealed that only CMV-hOATP1B3-transfected HEK293 tumors demonstrated a T1 contrast effect, which lasted for at 
least 5 hours.
Conclusion: The human endogenous OATP1B3 gene can be non-virally delivered into cells to induce transient OATP1B3 
expression, leading to gadoxetic acid-mediated enhancement on MRI. These results indicate that hOATP1B3 can serve as an 
MRI-reporter gene while minimizing the risk of long-term complications.
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protein-based optical imaging is probably the method most 
frequently used to assess gene expression. However, in spite 
of its many advantages, optical imaging suffers from limited 
imaging depth (3, 4), which may be a trivial limitation 
in ex vivo experiments, but is an obvious shortcoming for 
intravital imaging. Achieving a sufficient imaging depth 
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This study was approved by the institutional animal care 
and use committee of Yonsei University Severance Hospital 
(2014-0178) and Samsung Medical Center (20181013001).
Cell Lines and Cell Cultures
A HEK293 cell line was purchased from the Korean cell 
line bank. The cells were maintained in high-glucose 
Dulbecco’s modified Eagle’s medium containing 10% fetal 
bovine serum (Hyclone, Logan, UT, USA), 1% penicillin, 
and 1% streptomycin (Hyclone). HOATP1B3 cDNA in the 
pCMV3 vector (HG13013-UT, Sino biological Inc., Beijing, 
China) and the control vector CV011 (Sino biological Inc.) 
were transfected into HEK293 cells using LipofectamineTM 
2000 (Invitrogen, Carlsbad, CA, USA). To select transfected 
clones, 100 μg/mL hygromycin B (Invitrogen) was added to 
the cell cultures, and isolated colonies were picked using 
microscopy and grown separately. 
Preparation of a Phantom Contrast Agent and in Vitro 
Phantoms 
Either 12 μL of gadoxetic acid (Primovist®) or gadobenate 
dimeglumine (MultiHance®, Bracco Diagnostics Inc., 
Princeton, NJ, USA) was added to phosphate-buffered 
saline (PBS) to make a total volume 1 mL, and serial 1:10 
dilutions were made with PBS. PBS without contrast agent 
was used as a negative control. Each well of a 16-well 
polymerase chain reaction (PCR) strip was filled with the 
aforementioned diluents to make MRI contrast phantoms. 
Then strips were sealed and dipped in a 50-mL Falcon tube 
containing PBS. 
Gadoxetic acid or gadobenate dimeglumine in a volume 
of 1.2 μL was added to 1 mL of culture media, and serial 
1:10 dilutions with culture media were made to prepare 
culture media with different concentrations of the contrast 
agent. Cell phantoms were then prepared by incubating 
CMV promoter-human organic anion transporting polypeptide 
1B3 (CMV-hOATP1B3)- and CMV-blank-transfected HEK293 
cells in media containing one of the two contrast agents. 
After 24 hours, the cells were harvested and the cell pellets 
were placed in 16-well PCR strips. Empty spaces in the strip 
were filled with PBS, and the strips were sealed and dipped 
in 50-mL Falcon tubes containing PBS (Supplementary 
Materials). 
is particularly difficult in humans, as the human body is 
larger than that of most animals used in research, and is 
an important technical consideration for imaging of human 
patients.
Recent innovations in biology, including next-generation 
sequencing (5, 6), CRISPR-Cas9 gene editing (7, 8), 
and induced pluripotent stem cell technology (9, 10), 
are enabling treatment of diseases that were previously 
considered incurable (11-13). However, radiological studies 
based on anatomical imaging may not be effective in 
assessing the response to treatment. A reporter gene in 
human patients could be used in gene and cell therapy to 
assess the expression of a target gene or to visualize the 
bio-distribution of therapeutic cells (14).
Gadoxetic acid, which is sold under the tradename 
Primovist® (Bayer AG, Berlin, Germany), is a clinically-
approved contrast agent widely used for magnetic 
resonance imaging (MRI) of the liver. Approximately 
50% of an injected dose of gadoxetic acid is taken up by 
hepatocytes, and is subsequently excreted into the bile (15, 
16). Gadoxetic acid is transported from the bloodstream 
into hepatocytes by the organic anion transporting 
polypeptides (OATP) 1B1 and 1B3, which are only expressed 
in hepatocytes (17). Consequently, the normal liver 
parenchyma is selectively enhanced at the hepatobiliary 
phase (18). A few groups have used either mouse OATP1a1 
or human OATP1B3 as MRI gene reporters by transfecting 
target cells with viral vectors (19-22).
Although viral vectors ensure higher transfection 
efficiency and more stable expression of genes than 
non-viral transfection methods, they increase the risk 
of complications such as insertional mutagenesis (23). 
Overexpression of OATP1B3 has been reported to have 
undesirable effects in tumors (24), therefore raise a 
theoretical risk of unexpected biological influence that 
might be caused by persistent OATP1B3 expression induced 
by viral vectors. 
Because of these concerns, we believe that if human 
organic anion transporting polypeptide 1B3 (hOATP1B3) is 
to be used as a gadoxetic acid-mediated MRI-reporter gene 
in humans, it should be delivered using a non-viral vector. 
Here, we used a non-viral vector method to transfect the 
hOATP1B3 gene into HEK293 cells and evaluated hOATP1B3 
as a gadoxetic acid-enhanced MRI-reporter gene. The 
purpose of this study was to find an MRI-reporter gene that 
can be used to monitor gene or cell therapy and that can 




In Vivo MRI Using of Mouse Xenograph Tumors
Five million HEK293 cells transfected with CMV-hOATP1B3 
(n = 4) or CMV-blank (n = 4) were implanted in 8-week old 
male nude mice for in vivo growth as xenograft tumors. All 
animals were anesthetized in an induction chamber using 
a mixture of 3% isoflurane and 97% oxygen and examined 
with a horizontal-bore 9.4T micro-MRI scanner (Biospec 
94/20 USR, Bruker Biospin Inc., Billerica, MA, USA). During 
the procedure, anesthesia was maintained a mouth and 
nose mask. All animals were placed in a prone position in 
a dedicated animal cradle heated by a thermostat-driven 
water bath. For the contrast-enhanced study, gadoxetic 
acid, in a volume of 1.2 μL per g body weight, was injected 
through the tail vein. 
MRI was performed using a linear, polarized coil with an 
inner diameter of 40 mm that was developed for imaging of 
the mouse abdomen (Bruker Biospin Inc.). Pre-contrast T1 
weighted images (T1WIs) were obtained prior to gadoxetic 
acid injection and 5-minute, 30-minute, and 5-hour after 
injection. 
Pre-/-post T1WIs were obtained using the T1 spin echo 
rapid acquisition with relaxation enhancement sequence 
technique with the following parameters: echo time = 8.06 
ms, repetition time = 494 ms, field of view = 35 x 23 mm, 
matrix size = 256 x 256, slice thickness = 1 mm, flip angle = 
90°, number of excitation average 5, and bandwidth 2000. 
The total measurement time was approximately 5 minutes 
(Table 1). All images were acquired with fat suppression.
RESULTS
OATP1B3 Expression in CMV-hOATP1B3-Transfected HEK 
293 Cells
Confocal microscopy and western blotting revealed that 
CMV-hOATP1B3-transfected HEK293 cells, but not CMV-blank-
transfected cells, expressed hOATP1B3 protein in the cell 
membrane. Expression of hOATP1B3 remained high through 
the first 25 cell culture cycles that occurred during cell 
phantom preparation (Fig. 1), but gradually dropped after 
another 25 cycles, until only a relatively small fraction of 
cells expressed hOATP1B3 (Fig. 1). 
Table 1. Imaging Parameters Used for MRI
Sequence T1 Spin Echo RARE T1 Mapping
Pulse sequence 2D spin echo
RARE with 
variable TR
Matrix 256 x 256 128 x 128
TE 8.06 10
TR 494
200, 400, 800, 
1500, 3000 
NEX Average 5 1
Flip angle 90 90
Bandwidth Hz/pixel 2000 100
FOV (mm) 35 x 23 80 x 40
Section thickness (mm) 1 1
Slice spacing (mm) 1 1
Fat suppression
FOV = field of view, NEX = number of excitation, RARE = rapid 
acquisition with relaxation enhancement, TE = echo time, TR = 
repetition time, 2D = two-dimensionl
Fig. 1. Generating CMV-hOATP1B3 overexpressing HEK293 cells. 
A. Immunofluorescence staining and confocal microscopy of HEK293 
cells passed for 25 (upper row) or 50 (middle row) cycles after 
transfection with CMV-hOATP1B3; (lower row) CMV-blank transfected 
HEK293 cells for negative control (left column: x 20, right column: 
x 40, hOATP1B3 [red], DAPI [blue]). B. Western blot analysis of 
hOATP1B3 (upper row) and β-actin (lower row) in HEK293 cells 
transfected with (left) CMV-blank (negative control) or with CMV-
hOATP1B3 and passed for 25 (middle) or 50 (right) cycles. CMV-














































transfection and then implanted into the flanks of nude 
mice. CMV-blank-transfected HEK293 xenograft tumors were 
also implanted as a control. In vivo MRI was performed 
using a 9.4T scanner before and after an intravenous bolus 
injection of gadoxetic acid (1.2 μL/g body weight). The 
dosage of gadoxetic acid was determined from a previous 
reference, which translated the equivalent human dose from 
other species according to body surface area (26).
Liver parenchymal enhancement was observed in scans 
taken approximately 30 minutes after the gadoxetic acid 
injection in both CMV-hOATP1B3-transfected HEK293 
xenograft and CMV-blank-transfected HEK293 xenograft 
tumor-bearing mice (Fig. 3). We used this liver enhancement 
(27) as an internal reference for physiologic mouse OATP 
expression in hepatocytes. Both the CMV-hOATP1B3-
transfected HEK293 xenograft tumors and the control 
xenograft tumors showed heterogeneous enhancement, 
although enhancement of the CMV-hOATP1B3-transfected 
HEK293 xenograft appeared to be more prominent (Fig. 3). 
However, when we re-scanned the mice approximately 5 hours 
later, only the CMV-hOATP1B3-transfected HEK293 xenograft 
and not the control xenograft maintained perceivable 
enhancement (Fig. 3) and enhancement in the mouse liver 
was no longer observed (Fig. 3). 
Immunohistochemistry was used to detect OATP1B3 
protein in the xenograft tumors. In CMV-hOATP1B3-
transfected xenografts, both OATP1B3 positive- and 
negative-cells were present. In OATP1B3 positive cells, the 
protein signal was localized at the cell membrane (Fig. 4).
Transfection of HEK293 Cells with an Overexpressing 
hOATP1B3 Gene
Next, to increase the sensitivity of the reporter gene 
and to enable co-express of green fluorescent protein, we 
designed a modified hOATP1B3 gene with an enhanced 
capacity for hOATP1B3 expression. This modified gene, 
which was named CMV-Kozak-(codon-optimized) hOATP1B3-
IRES-GFP (Supplementary Materials), was transfected into 
HEK293 cells. Confocal microscopy revealed that, unlike 
normal hepatocytes or CMV-hOATP1B3-transfected HEK293 
cells, in which OATP1B3 is localized in the membrane (Fig. 
1) (28), in CMV-Kozak-(codon-optimized) hOATP1B3-IRES-
GFP-transfected cells, hOATP1B3 was localized mostly in 
the cytoplasm (Supplementary Fig. 4). MRI was performed 
on cell phantoms containing pellets of CMV-Kozak-(codon-
optimized) hOATP1B3-IRES-GFP-transfected cells that had 
been cultured with either gadoxetic acid or gadobenate 
MRI of in Vitro Cell Phantoms
We tested the function of two commercially available 
hepatocyte-selective gadolinium contrast agents (gadoxetic 
acid and gadobenate dimeglumine) known to be transported 
by OATP1 (25). Using a 9.4T micro-MRI, we first scanned 
a phantom containing each of the contrast agents diluted 
to various concentrations and confirmed that the agents 
both generated sufficient T1 contrast (Supplementary Fig. 
1). Next, to determine if hOATP1B3-expressing HEK293 cells 
can functionally induce the OATP1B3-mediated contrast 
enhancement effect, we made cell phantoms with the 
pellets of either CMV-hOATP1B3- or CMV-blank-transfected 
HEK293 cells that had been cultured for 24 hours either 
with gadoxetic acid or gadobenate dimeglumine. In MRI 
scans, only CMV-hOATP1B3-transfected HEK293 cell pellets 
cultured in the presence of gadoxetic acid (1.2 μL/mL 
media) demonstrated perceivable contrast enhancement 
(Fig. 2A, Supplementary Fig. 2). The pellets of cells cultured 
at lower gadoxetic acid concentrations and the pellets of 
cells cultured in gadobenate dimeglumine did not show 
significant contrast enhancement (Fig. 2, Supplementary 
Figs. 2, 3).
MRI of in Vivo Xenograft Tumor-Bearing Mice
Based on the cell phantom results, we proceeded with in 
vivo studies using gadoxetic acid. To mimic the conditions 
of the cell phantom, the HEK293 cells were passed through 
approximately 25 culture cycles after CMV-hOATP1B3-
Fig. 2. 9.4T MRI T1WIs of (A) gadoxetic acid and (B) 
gadobenate dimeglumine based cell phantoms. Either CMV-
hOATP1B3 transfected HEK293 cells (left column) or CMV-blank 
transfected control HEK293 cells (right column) were pelleted. 



























in culture media 1 mL
Contrast 0.12 μL
in culture media 1 mL
Contrast 0.012 μL
in culture media 1 mL
Contrast 0.0012 μL
in culture media 1 mL
Contrast 0.00012 μL
in culture media 1 mL
Contrast 120 μL









dimeglumine, but no significant T1 enhancement was 
observed (Supplementary Figs. 5, 6).
DISCUSSION
In this study, our goal was to identify a reporter gene 
that can safely be used in humans undergoing gene or cell 
therapy to monitor gene expression or track genetically 
labeled cells (2). Human imaging is more challenging than 
animal imaging because 1) the human body is much larger 
than the bodies of most animal used in research, making it 
more technically challenging to achieve a sufficient imaging 
depth; 2) imaging methods used on humans need to be 
both robust and convenient if they are to be integrated 
into the daily workflow; 3) for safety reasons, in humans, 
the reporter gene should preferably be an endogenous 
human gene and not an exogenous gene such as a luciferase 
or fluorescent protein (2); and 4) if possible viral vectors 
should not be used to deliver the reporter gene in humans, 
as integration of virus DNA into chromosomes can cause 
unexpected complications (23).
We believe that gadoxetic acid-enhanced MRI can be 
exploited to meet the aforementioned conditions. MRI is 
a widely used diagnostic imaging technique that provides 
sufficient imaging depth sufficient to scan the whole body 
(29). Moreover, MRI can be used to produce a detailed 
anatomical evaluation and soft tissue characterization, 
and this information, along with information about the 
expression of a target gene, can be useful in assessing the 
effects of gene or cell therapy on patients.
Several groups have made significant progress in 
developing MRI-reporter genes and using these genes in 
biomedical research (14, 30-34). To be useful, an MRI-
reporter gene must be capable of detecting expression of 
the target gene at an adequate signal-to noise-ratio. Most 
MRI-reporter genes developed to date have disadvantages, 
including low detection sensitivity, inadequate signal 
changes, and requirement of substrates with undesirable 
Fig. 3. 9.4T MRI T1WIs of (A) CMV-blank transfected xenograft tumor and (B) CMV-hOATP1B3 transfected xenograft tumor-bearing 























resistance (24). Moreover, as OATP1B3 is responsible for 
the cellular transportation of many drugs (37), the non-
physiologic, sustained overexpression of this gene may alter 
the action of medications taken by human patients. 
We believe that a non-viral method is a safer than a viral 
method for delivering the OATP1B3 into humans. However, 
because non-viral vectors are often inefficient in gene 
delivery and induce transgenic expression transiently (23), 
doubts have been raised as to whether non-viral methods 
of gene delivery will be technically feasible. Here, we show 
that OATP1B3 performs adequately as a reporter gene when 
delivered using non-viral vector. 
Our analysis was performed using the human OATP1B3 
gene constitutively activated with a CMV promoter (CMV-
hOATP1B3). We chose to use the human OATP1B3 gene 
rather than the mouse OATP1a1 gene because the human 
pharmacokinetics, that have limited their usefulness (14, 
35). Many of these MRI-reporter genes, which have primarily 
been used for research, mostly require genes exogenous to 
human and/or metal-complex injection which may raise 
safety issues if applied to human patients. 
Recent progress has been made using OATP1a1 from 
mouse and OATP1B3 from humans as gadoxetic acid-
dependent MRI-reporters (19-22). But these studies have 
focused on the imaging in animals, and the viral vector 
delivery method used in these studies may be potentially 
unsafe for humans for the following reasons. First, viral 
vectors can cause insertional mutagenesis, leading to 
malignant transformation of cells (23, 36). Second, 
persistent OATP1B3 expression induced by viral vectors 
may have adverse effects such as reducing transcriptional 
activity of p53, which can lead to tumor apoptotic 
Fig. 4. Hematoxylin and eosin staining (upper: x 10, x 40) and hOATP1B3 immunohistochemistry (lower: x 10, x 40) of in vivo 
xenograft tumor specimens. 





endogenous gene is less likely to elicit an immune 
response in patients (2). The OATP1B3 reporter gene was 
transfected into HEK293 cells using Lipofectamine, a non-
viral delivery method. Theoretically, a gene transfected 
using Lipofectamine is unlikely to become integrated 
into the chromosome; therefore, its expression is likely 
to be transient. We observed that in most cells hOATP1B3 
expression levels remained steady for 25 in vitro subculture 
cycles, and then gradually faded away (Fig. 1). The 25 
culture cycles through which hOATP1B3 was expressed 
allowed ample time to perform MRI imaging studies, and 
we believe that the duration of hOATP1B3 expression will 
be sufficient to establish therapeutic protocols in humans. 
An ideal reporter gene should be biologically inert and have 
little or no influence on the cells in which it is expressed 
(35). We recognize that it is possible that hOATP1B3 
overexpression may have unintended consequences and 
believe that our strategy of limiting the expression of 
hOATP1B3 to a limited period after gene delivery will reduce 
the risk of undesirable side effects. We anticipate that our 
method may be adapted for the monitoring of therapeutic 
cells. For example, the OATP1B3 gene could be non-virally 
delivered into induced pluripotent stem cells or immune 
cells in vitro so that the cells could be visualized by 
gadoxetic acid-enhanced MRI after injection into the body.
When in vivo MRI of xenograft-bearing mice was 
performed 30 minutes after gadoxetic acid injection, 
the liver displayed enhancement as expected, given 
the physiological role of mouse OATP expression in 
hepatocytes (27). CMV-hOATP1B3-transfected xenograft 
tumors displayed heterogeneous enhancement until 5 
hours after the gadoxetic acid injection. In contrast, the 
Fig. 4. Hematoxylin and eosin staining (upper: x 10, x 40) and hOATP1B3 immunohistochemistry (lower: x 10, x 40) of in vivo 
xenograft tumor specimens. 





In conclusion, we show here that the human endogenous 
OATP1B3 gene can be used as a gadoxetic acid-mediated 
MRI-reporter gene, and that this gene can be transiently 
expressed in target cells without using viral vectors, which 
minimizes the risk of long-term complications. We believe 
that the hOATP1B3 gene can be used to monitor gene 
expression during human gene or cell therapy, and can also 
be used to assess the bio-distribution of therapeutic cells. 
Supplementary Materials
The Data Supplement is available with this article at 
https://doi.org/10.3348/kjr.2019.0903.
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